News Image

Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction

Provided By GlobeNewswire

Last update: May 21, 2025

Investigator-initiated Phase 2 trial to evaluate TNX-102 SL’s potential to reduce severity of acute stress reaction (ASR) and frequency of acute stress disorder (ASD)

Read more at globenewswire.com

TONIX PHARMACEUTICALS HOLDIN

NASDAQ:TNXP (7/23/2025, 8:00:00 PM)

After market: 45.72 +0.2 (+0.44%)

45.52

+0.77 (+1.72%)



Find more stocks in the Stock Screener

Follow ChartMill for more